Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploring perceptions towards health and child nutrition: A qualitative study among tribal mothers in Southern Karnataka.

PloS one·2026

Same author

Combined scalp rotation and temporalis muscle flap for orbital exenteration reconstruction.

Orbit (Amsterdam, Netherlands)·2026

Same author

Coverage, delivery models, and implementation challenges of the community driven nutritional supplementation initiative for people with TB: A mixed methods study from Puducherry, India.

PLOS global public health·2025

Same author

Interesting Case of Celphos Poisoning with G6PD Deficiency: Is There a Correlation?

The Journal of the Association of Physicians of India·2025

Same author

Experiential learning in autism intervention module training.

Medical education·2025

Same author

Rare case of hard palate mucomycosis complicated by peri-orbital swelling: A diagnostic challenge.

Radiology case reports·2025

Search research articles

Related Experiment Video

Updated: Jun 1, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Dasatinib-Induced Gynecomastia: A Case Report.

Himanshi Kaushik¹, Kanchan D Devde¹, Nishtha Manuja²

¹Medical Oncology, Jawaharlal Nehru Medical College, Wardha, IND.

|January 22, 2025

Summary

This summary is machine-generated.

Dasatinib, a leukemia drug, can rarely cause gynecomastia (male breast enlargement). This case report details a patient experiencing this side effect, highlighting the need for monitoring and further research into its mechanisms and management.

Area of Science:

Oncology
Endocrinology
Pharmacology

Background:

Gynecomastia, the abnormal enlargement of male breast tissue, is a rare adverse effect of dasatinib.
Dasatinib is a tyrosine kinase inhibitor used for chronic myeloid leukemia (CML).

Keywords:

blast cell bone marrow aspiration chronic myeloid leukemia testosterone tyrosine kinase inhibitor

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Experiment Videos

Last Updated: Jun 1, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023